Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immedica AB

https://immedica.com/

Latest From Immedica AB

Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial

The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.

Clinical Trials Cancer

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Deal Watch Business Strategies

Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product

The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.

Clinical Trials Rare Diseases

Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.

Deals Business Strategies
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Impilo AB, Medical Need Europe AB
UsernamePublicRestriction

Register